Skip to main content
Premium Trial:

Request an Annual Quote

Ian Tarr, Rebecca Lawrence, Stephanie Kappus, Laura Thomson, James Jacketti, Markus Wolfinger, Dieter Matheis, Stephan Mahn

Current BioData announced the following appointments this week: Ian Tarr as CEO; Rebecca Lawrence as director of editorial services; Stephanie Kappus as CTO; Laura Thomson as business development director, and James Jacketti as senior vice president for sales and marketing.
Tarr most recently was executive vice president with Thomson Scientific where he was responsible for the company products and services for the pharmaceutical, biotechnology, and chemical industries.
Lawrence was the publishing manager at Drug Discovery Today. Thomson has worked for the British Standards Institute and Thomson Corp. Kappus was with GeneBio and the European Bioinformatics Institute. Jacketti managed US sales operations at Current Drugs.
Current BioData is a joint venture between Geneva Bioinformatics and the Science Navigation Group and is developing products and services to assess the impact of new protein research on drug R&D. The company expects its first products to launch early next year, it said in a statement.

Markus Wolfinger was appointed to the advisory board of CyBio, the company announced this week. Wolfinger is the CFO of Stratec Biomedical Systems. Dieter Matheis, who had been the board’s chairman, resigned Sept. 30 for personal reasons, the company said. He was replaced as chairman by Stephan Mahn.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.